



Nebraska Medicaid
Pharmaceutical and Therapeutics Committee Agenda
WEDNESDAY November 3, 2021

Mahoney State Park, Peter Kiewit Lodge
28500 West Park Hwy, Ashland, NE 68003

*A State Park Permit is required or a daily permit fee of \$6 (NE licensed vehicles) or \$8 (non-Nebraska resident) at the gate
and

Virtual Webinar via Zoom

Meeting Registration Link:

https://magellanhealth.zoom.us/webinar/register/WN_FS3TRbbIQp68Cr349WiDmA

08:00 a.m. Registration

08:55-9:00a.m. Webinar opens for Public Attendees

09:00 a.m. Opening of Public Meeting and Call to Order
Committee Business

- Roll Call
- Conflict of Interest Updates
- Approval of Meeting Minutes: May 13, 2021
- Election of Board Chair and Vice Chair
- Department Information

09:15-10:15 a.m. Public Testimony (for Products Recommended to be Non-Preferred)
https://nebraska.fhsc.com/Downloads/NE_PT_PublicTestimony_Guidelines.pdf
<http://dhhs.ne.gov/Pages/Pharmacy-Drug-Testimony.aspx>

- *Modifications to Public Testimony guidelines to accommodate for Virtual Webinar
- Public Testimony Registration Applications will only be accepted by online registration – No faxed/mailed requests will be accepted
- If handouts are being provided, they must be submitted with testimony application, no later than the testimony deadline, for dissemination to the committee

10:15-11:15 a.m. Committee Closed Session (offline)- Public Webinar will close

11:15-12:00 p.m. Resume Open Session, webinar re-opens for Public Attendees

- Consideration of Consent Agenda
- Consideration of Therapeutic Class Reviews

12:00-1:00 p.m. Working Lunch for Committee Members- Closed Session

1:00-5:00 p.m. Committee Open Session- Consideration of Therapeutic Class Reviews- Resume Open Session
Break (if required)

4:30-5:00 p.m. Old Business

- Hepatitis C data
- Adjournment: **Next meeting: Wednesday May 11, 2022**

Consent Agenda: (Therapeutic Categories with Unchanged Recommendations)

The following classes have no changes recommended by the Department and will all be voted on as a group, unless a class is removed from the Consent Agenda.

Alzheimer's Agents	NSAIDS
Anthelmintics	Oncology, Oral- Breast
Anti-Allergens, Oral	Oncology, Oral – Hematologic
Antihistamines, Minimally Sedating	Oncology, Oral – Lung
Antihypertensives, Sympatholytics	Oncology, Oral – Other
Antihyperuricemics	Oncology, Oral – Prostate
Antipsoriatics, Oral	Oncology, Oral – Renal Cell
Antipsoriatics, Topical	Oncology, Oral – Skin
Anxiolytics	Ophthalmic Antibiotic-Steroid Combinations
Bile Salts	Ophthalmic, Antibiotics
COPD Agents	Ophthalmic, Anti-Inflammatories
Cough and Cold, Opiate	Ophthalmic, Anti-
Enzyme Replacement, Gaucher's Disease	Inflammatory/Immunomodulator
Epinephrine, Self-Injected	Otic Antibiotics
Erythropoiesis Stimulating Proteins	Otic Anti-Infectives & Anesthetics
Glucocorticoids, Inhaled	Progesterone (hydroxyprogesterone caproate)
Glucocorticoids, Oral	Sedative Hypnotics
Hemophilia Treatment	Sickle Cell Treatment
Histamine II Receptor Blockers	Steroids, Topical High
Idiopathic Pulmonary Fibrosis	Steroids, Topical Low
Immunomodulators, Atopic Dermatitis	Steroids, Topical Medium
Immunomodulators, Topical	Steroids, Topical Very High
Intranasal Rhinitis Agents	Stimulants and Related Drugs
Leukotriene Modifiers	Thrombopoiesis Stimulating Proteins
Methotrexate	

Therapeutic Class Reviews: (Therapeutic Categories with New Recommendations)

Antiparkinson's
Bronchodilators, Beta Agonist
Colony Stimulating Factors
Cytokine and CAM Antagonists
Immunomodulators, Asthma
Movement Disorders
Ophthalmic, Allergic Conjunctivitis
Ophthalmic, Glaucoma Agents